Does INOTUZUMAB OZOGAMICIN Cause Neoplasm recurrence? 29 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 29 reports of Neoplasm recurrence have been filed in association with INOTUZUMAB OZOGAMICIN (Besponsa). This represents 1.3% of all adverse event reports for INOTUZUMAB OZOGAMICIN.
29
Reports of Neoplasm recurrence with INOTUZUMAB OZOGAMICIN
1.3%
of all INOTUZUMAB OZOGAMICIN reports
13
Deaths
5
Hospitalizations
How Dangerous Is Neoplasm recurrence From INOTUZUMAB OZOGAMICIN?
Of the 29 reports, 13 (44.8%) resulted in death, 5 (17.2%) required hospitalization, and 1 (3.4%) were considered life-threatening.
Is Neoplasm recurrence Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for INOTUZUMAB OZOGAMICIN. However, 29 reports have been filed with the FAERS database.
What Other Side Effects Does INOTUZUMAB OZOGAMICIN Cause?
Death (253)
Febrile neutropenia (230)
Venoocclusive liver disease (229)
Neoplasm progression (158)
Pyrexia (151)
Off label use (146)
Sepsis (119)
Venoocclusive disease (109)
Thrombocytopenia (108)
Platelet count decreased (107)
What Other Drugs Cause Neoplasm recurrence?
CYCLOPHOSPHAMIDE (293)
PALBOCICLIB (248)
DOXORUBICIN (240)
VINCRISTINE (239)
CYTARABINE (223)
METHOTREXATE (198)
CARBOPLATIN (170)
RITUXIMAB (163)
ETOPOSIDE (156)
PREDNISONE (144)
Which INOTUZUMAB OZOGAMICIN Alternatives Have Lower Neoplasm recurrence Risk?
INOTUZUMAB OZOGAMICIN vs INSULIN
INOTUZUMAB OZOGAMICIN vs INSULIN ASPART
INOTUZUMAB OZOGAMICIN vs INSULIN ASPART\INSULIN DEGLUDEC
INOTUZUMAB OZOGAMICIN vs INSULIN BEEF
INOTUZUMAB OZOGAMICIN vs INSULIN DEGLUDEC